FindTrial
Sign In

TPF induction chemotherapy

DRUG4 trials

Sponsors

Charite University, Berlin, Germany, Shanghai Jiao Tong University School of Medicine

Conditions

Carcinoma, Squamous CellMouth NeoplasmsSquamous Cell Carcinoma of the HeadSquamous Cell Carcinoma of the NeckStage III Oral Cavity Squamous Cell CarcinomaStage IVA Oral Cavity Squamous Cell Carcinoma

Phase 2

InductionChemo-Radio-Antibody-Treatment
CompletedNCT01181401
Charite University, Berlin, GermanySquamous Cell Carcinoma of the Head, Squamous Cell Carcinoma of the Neck
Start: 2010-08-31End: 2015-08-31Updated: 2019-01-31
TPF Induction Chemotherapy for Locally Advanced and Resectable Oral Squamous Cell Carcinoma
CompletedNCT01542931
Shanghai Jiao Tong University School of MedicineStage III Oral Cavity Squamous Cell Carcinoma, Stage IVA Oral Cavity Squamous Cell Carcinoma
Start: 2008-01-31End: 2015-12-31Updated: 2017-08-21
GDF15 Based TPF Induction Chemotherapy for OSCC Patients
NCT02285530
Shanghai Jiao Tong University School of MedicineCarcinoma, Squamous Cell, Mouth Neoplasms
Start: 2019-12-01End: 2025-12-31Target: 72Updated: 2023-04-05
A Phase II Trial of TPF Induction Chemotherapy in cN2 OSCC Patients
TerminatedNCT02285543
Shanghai Jiao Tong University School of MedicineCarcinoma, Squamous Cell, Mouth Neoplasms
Start: 2016-12-01End: 2023-07-30Updated: 2023-11-22

Related Papers

Derived Neutrophils to Lymphocyte Ratio Predicts Survival Benefit from TPF Induction Chemotherapy in Local Advanced Oral Squamous Cellular Carcinoma
Cancers2024-07-30
Cyclin D1 overexpression enhances chemosensitivity to TPF chemotherapeutic agents via the caspase‑3 pathway in oral cancer
Oncology Letters2020-08-243 citations
High‐risk lymph node ratio predicts worse prognosis in patients with locally advanced oral cancer
Journal of Oral Pathology and Medicine2020-05-2518 citations
Normal BMI predicts the survival benefits of inductive docetaxel, cisplatin, and 5-fluorouracil in patients with locally advanced oral squamous cell carcinoma.
2019-12-028 citations
Relationship of low stathmin expression and benefit from TPF induction chemotherapy and its role in chemoresistance via mutant p53 in oral cancer.
Journal of Clinical Oncology2018-05-201 citations
Elevated growth differentiating factor 15 expression predicts long‑term benefit of docetaxel, cisplatin and 5‑fluorouracil induction chemotherapy in patients with oral cancer
Oncology Letters2018-03-2212 citations
Standard or split TPF induction chemotherapy followed by bioradiation: ICRAT randomized phase II study.
Journal of Clinical Oncology2016-05-204 citations
GDF15 is a potential predictive biomarker for TPF induction chemotherapy and promotes tumorigenesis and progression in oral squamous cell carcinoma.
2014-03-2453 citations